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Abstract 
The ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, 
edelfosine (ET-18-OCH3) is the prototype molecule of a promising class of antitumour 
drugs named alkyl–lysophospholipid analogues (ALPs) or antitumor ether lipids. This 
drug presents a very important drawback as can be the dose depending haemolysis when 
administered intravenously. Lipid nanoparticles have been lately proposed for different 
drug encapsulation as an alternative to other controlled release delivery systems, such as 
liposomes or polymeric nanoparticles. The aim of this study was to develop a lipid 
nanoparticulate system that would decrease systemic toxicity as well as improve the 
therapeutic potential of the drug. Lipids employed were Compritol® 888 ATO and 
stearic acid. The nanoparticles were characterized by photon correlation spectroscopy 
for size and size distribution, and atomic force microscopy (AFM) was used for the 
determination of morphological properties. By both differential scanning calorimetry 
(DSC) and X-ray diffractometry, crystalline behaviour of lipids and drug was assessed. 
The drug encapsulation efficiency and the drug release kinetics under in vitro conditions 
were measured by HPLC–MS. It was concluded that Compritol® presents advantages as 
a matrix material for the manufacture of the nanoparticles and for the controlled release 
of edelfosine. 
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1. Introduction 
Edelfosine (ET–18–OCH3, 1-O-octadecyl-2-O-methyl-rac-glycero-3-
phosphocholine) is the prototype of a promising class of antitumor agents, collectively 
known as alkyl-lysophospholipid analogues (ALPs) or antitumor ether lipids, that do 
not target the DNA, but affect the cell membrane and the apoptotic machinery of the 
cancer cell [1]. Phase I studies have shown a good tolerability of the drug but with 
haematological and systemic side effects [1, 2]. However, although edelfosine has been 
shown to exert potent antineoplastic effects in vitro [3, 4], the antitumor activity in 
phase II clinical studies has been only moderate [5]. Moreover, ALPs show manifold 
biological effects in addition to their antineoplastic actions, including an antiparasitic 
effect on Leishmania [6] as well as an inhibition of the cell membrane phospholipid 
turnover [7] and a potent inhibition of neovascularization [8], protein kinase C and 
Na+/K+-ATPase [9]. 
Edelfosine has also been given intravenously, but this provoked haemolysis as a 
major side effect [10]. This led to the only formulation developed so far, the TLC ELL-
12, in which edelfosine was included into liposomes [11] to avoid the haemolytic 
toxicity of the drug. However, the main inconvenience of liposomes is their rapid 
clearance from plasma in comparison with other delivery systems. 
Lipid nanoparticles have been proposed as an alternative for the existing traditional 
particulate systems, such as previously mentioned liposomes or polymeric 
nanoparticles. These particulate systems made from solid lipids started being developed 
in the early nineties. They provide physical stability, controlled release and a wide 
variety of application routes (parenteral, oral, dermal, ocular, pulmonary and rectal) [12-
16].  
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Lipid nanoparticles are basically composed of a high melting point lipid that acts as 
a solid core, covered by surfactants. Lipids used to form these matrices are 
biodegradable raw materials that are physiologically tolerated [17]: triglycerides (i.e. 
tristearin), partial glycerides (i.e. Compritol), fatty acids (i.e. stearic acid), steroids (i.e. 
cholesterol) or waxes (i.e. cetyl palmitate) [18]. 
The formulation methods are also diverse. Emulsion formation and solvent 
evaporation method has been widely used for particle formation, although other 
methods like high pressure homogenization [18], solvent diffusion methods in aqueous 
solutions [19] or hot emulsion methods [18, 20] have also been employed. Drawbacks 
associated to this kind of formulations, like limited drug loading capacity, adjustment of 
drug release profile and potential drug expulsion during storage have been reported 
[21]. Besides, drug loading capacity is limited by the solubility of the drug in the lipid 
melt, the structure of the lipid matrix and the polymorphic state of the lipid matrix. 
Comparing with the previously mentioned liposomes, the main improvement of the 
lipid nanoparticles is their physical and chemical long-term stability up to 12 – 24 
months [13], even though an increase in particle size has been reported in a lesser time 
[22]. As a feasible solution for this setback, the freeze-drying process has shown to 
increase physicochemical stability of lipid particles over large periods of time [23]. 
Taking into account this information, the aim of this study was to develop a new 
formulation which would provide a controlled release for the antitumor lipid edelfosine, 
in order to improve its therapeutic activity. 
. 
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2. Materials and Methods 
2.1 Materials  
Edelfosine was from INKEYSA (Barcelona, Spain). Compritol® 888 ATO was a gift 
of Gattefossè (Cedex, France). Stearic acid and Tween® 80 were purchased from Roig 
Farma (Barcelona, Spain). Poly (vinyl alcohol) 88 % hydrolyzed (MW: ~ 125,000) and 
Phosphate Buffer Saline (PBS) were provided by Sigma-Aldrich (Spain). Chloroform 
and ethyl acetate were obtained from Panreac Química S.A. (Barcelona, Spain). All 
solvents employed for the chromatographic analysis were of analytical grade. Formic 
acid 99% for mass spectroscopy was purchased from Fluka (Spain) and methanol was 
obtained from Merck (Spain). All other chemicals were of reagent grade and used 
without further purification. Amicon Ultra–15 centrifugal filter devices were purchased 
from Millipore (Cork, Ireland). 
 
2.2 Preparation of lipid nanoparticles 
Lipid nanoparticles were prepared by the emulsification/solvent evaporation 
method. For the simple emulsion solvent evaporation method, edelfosine and the lipid 
(either Compritol® or stearic acid) were dissolved in chloroform. This solution was 
emulsified with a 0.5 % or 1 % Tween 80 solution by ultrasonication using a 
MicrosonTM ultrasonic cell disruptor (NY, USA). The O/W emulsion formed was 
magnetically stirred for 45 minutes and subjected to low vacuum rotary evaporation for 
the complete elimination of the organic solvent. Particles were centrifuged at 4500 g for 
40 minutes using an Amicon Ultra–15 filter device and washed twice with distilled 
water. The obtained particular suspension was fast frozen under –80 ºC for at least 3 
hours and freeze-dried in order to store it at 4 ºC. For the double emulsion (W/O/W), 
edelfosine was dissolved in 100 μl of a 1 % Tween 80 solution and emulsified with 1 ml 
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of ethyl acetate. This first W/O emulsion was then emulsified with 10 ml of a 1 % 
Tween 80 solution. Following steps were the same to the ones of the simple emulsion 
solvent evaporation method. 
 
2.3 Encapsulation efficiency 
Edelfosine was extracted by dissolving 10 mg of nanoparticles in 1 ml of chloroform 
and then mixed with 3 ml of ultra pure water. The mixture was vortexed for 1 minute 
and then centrifuged at 9500 g for 10 minutes. The supernatant was analysed by a 
HPLC–MS method, which is a slight modification of a previously developed method 
[24]. The apparatus used for the HPLC analysis was a Model 1100 series LC coupled 
with an atmospheric pressure (AP)-electrospray ionization (ESI) mass spectrometer (HP 
1100 with MSD VL, Waldbronn, Germany). Data acquisition and analysis were 
performed with a Hewlett-Packard computer using the ChemStation G2171 AA 
programme. Separation was carried out at 50 ºC on a reversed-phase, 150 mm × 3 mm 
column packed with C18, 5 μm silica reversed-phase particles (Gemini®) obtained from 
Phenomenex® (Torrance, CA, USA). This column was preceded by a reversed-phase, 
C18, 5 μm guard column (SecurityGuard®, 20 mm × 4 mm, Phenomenex®, Torrance, 
CA, USA). The mobile phase was a mixture of methanol–1 % formic acid (95:5, v/v). 
Separation was achieved by isocratic solvent elution at a flow-rate of 0.5 ml/min. The 
mass spectrometer was operated in the positive ESI mode. The detection of edelfosine 
was performed by selected ionization monitoring (SIM) mode. The mass spectrometer 
was programmed to monitor the ion of edelfosine at m/z 524.40. Typical retention time 
was 3.65 minutes. 
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2.4 Nanoparticle characterization 
2.4.1 Particle size, size distribution  and zeta potential 
Particle size and distribution of the nanoparticles were measured by photon 
correlation spectroscopy (PCS) using a Zetasizer Nano (Malvern Instruments, UK). 
Each sample was diluted with distilled water until the appropriate concentration of 
particles was achieved to avoid multiscattering events. The obtained homogenous 
suspension was examined to determine the volume mean diameter, size distribution and 
polydispersity.  
The electrophoretic mobility and zeta potential were determined by Laser Doppler 
Velocimetry using a Zetasizer Nano (Malvern Instruments, UK).  
 
2.4.2 Morphology 
Atomic force microscopy (Cervantes AFM System, Nanotec Electrónica, S.L., 
Spain) was employed to determine the shape and surface morphology of the 
nanoparticles. AFM was conducted with Nanoscope IIa IIIa in the tapping mode. The 
nanoparticle sample was mounted on a metal stab and scanned by the AFM maintained 
in a constant temperature and vibration time environment.  
 
2.4.3 Thermal analysis of freeze-dried lipid nanoparticles 
The thermal characteristics of selected batches of nanoparticles were determined by 
differential scanning calorimetry thermal analysis using a 2920 DSC (Universal V3.6C 
TA Instruments, USA). The scan rate was 10 ºC/min in the temperature range from –10 
ºC to 275 ºC and a N2 flow of 20 L/min. An empty pan was used as reference standard. 
Indium (purity ≥99.95 %, Fluka, Switzerland) was employed to check the calibration of 
the calorimetric system. 
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2.4.4 X-ray studies of freeze-dried lipid nanoparticles 
X-ray diffraction measurements were performed in order to clearly elucidate the 
solid state of both lipids and drug in lipid nanoparticles, using a Bruker D8 Advance X-
ray diffractometer (Bruker Biosciences Española, S.A., Spain). The X-ray diffractogram 
was scanned with the diffraction angle increasing from 2° to 40°, 2θ angle, with a step 
angle of 0.02° and a count time of 1 s at a constant temperature of 25 ºC.  
 
2.5 In vitro release studies 
The release rate of edelfosine from lipid nanoparticles was measured in PBS 
medium (pH 7.4). Briefly, 5 mg of nanoparticles were dispersed in 1 ml of buffer 
solution and maintained at 37 ºC under stirring (260 rpm). At appropriate time intervals, 
samples were centrifuged (23500 g, 10 minutes), supernatants were filtrated with a 0.45 
μm pore diameter filter and kept at –20 ºC until further HPLC–MS analysis was 
conducted as previously described. Three samples were employed for each time and the 
study was performed in triplicate. 
The mean in vitro dissolution time (MDT), a model-independent in vitro parameter 
that shows the meantime for edelfosine to release from the lipid nanoparticles under in 
vitro release conditions, was calculated according to the equation: 
∞
=
M
ABC
MDT vitroin    Eq. (1) 
where  is the area between the release curve and its asymptote, calculated by 
the trapezoidal rule from time zero to the last measured time point, and is the total 
amount of released drug at this time point. The release rate constant (k
vitroinABC
∞M
d) was calculated 
by the expression kd = 1/MDT. 
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3. Results and discussion 
3.1 Particle size, size distribution and zeta potential 
Structurally, edefosine has a structure of an amphifile, with a part of the molecule 
exhibiting hydrophobicity and another part exhibiting hydrophilicity, like a surface–
active agent (Fig.1).  
Edelfosine-loaded lipid nanoparticles were obtained by either simple or multiple 
emulsion solvent evaporation method, and freeze-dried. These nanoparticles were then 
characterized to assess the effect of the different lipids and surfactant concentrations on 
mean particle size, size distribution and surface charge. 
Using lipids as matrices for the particles, different characteristics can be obtained by 
optimizing the formulation parameters such as type of lipids, surfactants, organic 
solvents and emulsifying procedure chosen [18]. The presence of an anionic surfactant 
is important to reduce the dynamic interfacial tension and to stabilize the 
nanosuspension. The surfactant is adsorbed on the nanoparticle surface, increasing the 
steric repulsion between particles. In this study, Tween® 80 was tested at two different 
concentrations (w/v), being sufficient to obtain small lipid nanoparticles and permitting 
the removal of its excess by centrifugation and washing. 
The average size and polydispersity indices of lipid nanoparticles formulated with 
different lipids are reported in Table 1. All data are expressed as mean value ± standard 
deviation. For all lipids, it was possible to obtain submicron sized lipid nanoparticles 
with two different concentrations of Tween® 80. In fact, all formulations showed a 
mean diameter in the range of 300 – 600 nm. There was a decrease in size of particles 
when formulated with edelfosine (data not shown), probably due to the effect of 
edelfosine as a surfactant agent. Smallest particles were obtained using stearic acid, 
chloroform and an aqueous solution of Tween® 80 at a concentration of 1 %. The 
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polydispersity index (PDI) value was in the range of 0.2 – 0.6 for all lipid nanoparticles 
investigated.  
Zeta potential can make a prediction about the stability of colloid dispersions. A 
high zeta potential (> 30 mV) can provide an electric repulsion to avoid the aggregation 
of particles [25]. The incorporation of edelfosine into lipid nanoparticles had no 
significant influence on the zeta potentials of particles, which was negative in all cases. 
However, as the concentration of surfactant was increased in the formulation the zeta 
potential was found to be more negative (Table 1). This could be due to the adsorption 
of the surfactant on the particle surface, forming a denser surfactant film, thus eliciting a 
reduced electrophoretic mobility.  
 
3.2 Drug entrapment efficiency and loading capacity 
Over the past few years many different drugs had been successfully incorporated in 
lipid nano– or microparticles [20, 26-28]. Relatively higher drug encapsulation 
efficiency was one of the major advantages of lipid nanoparticles. It is also known that 
the lipid crystalline structure related to the chemical nature of the lipid is a key factor to 
determine whether a drug will be expelled or firmly incorporated into the carrier 
systems. In the nanoparticle structure, the lipid forming highly crystalline state with a 
perfect lattice would lead to drug expulsion. On the other hand, imperfections (lattice 
defects) of the lipid structure could offer space to accommodate the drugs [29]. As a 
result, the structure of less ordered arrangement in the nanoparticles would be beneficial 
to the drug loading capacity like the samples in this study.  
From the results listed in Table 2, it can be observed that the entrapment efficiency 
of edelfosine in the lipid nanoparticles prepared by the simple emulsion solvent 
evaporation method ranged from about 4 to 10 % for stearic acid nanoparticles. On the 
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other hand, nanoparticles formulated using Compritol® encapsulated more than 80 % of 
the drug (Table 2). This high encapsulation efficiency in comparison to the stearic acid 
nanoparticles is likely to be due to the partially amorphous state of the Compritol® in 
the formulation, which allows more edelfosine to be incorporated among lipid chains. It 
can also be observed that the emulsifier concentrations investigated in this study (0.5 % 
and 1 % Tween 80) do not affect the encapsulation efficiency. 
On the other hand, lipid nanoparticles prepared by the multiple emulsion solvent 
evaporation method showed very low encapsulation efficiency, less than 1 % (data not 
shown). 
 
3.3 Morphology 
In order to investigate the shape and surface morphology of the Compritol® 
nanoparticles, atomic force microscopy was employed. The AFM images reveal the fine 
structure of the Compritol® lipid nanoparticle surface (Fig. 2A). They give clear 3D 
morphological images of spherical nanoparticles of sub–400 nm diameter and they also 
confirm that there was no aggregation or adhesion among the nanoparticles (Fig. 2C). 
Furthermore, the surface morphology of the nanoparticles could be seen closely from 
the AFM images. It was noticeable from the zoom–in picture (Fig. 2B) the smooth 
surface morphology of the nanoparticles. 
 
3.4 DSC and X-ray diffractometry assays 
Lipid nanoparticles were analysed by DSC and X-ray diffractometry to investigate 
the crystal pattern of both edelfosine and lipids, because this aspect could influence the 
in vitro and in vivo release of the drug from the systems. To probe this effect, analysis 
were performed on the following samples: edelfosine; Compritol® 888 ATO; stearic 
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acid; edelfosine loaded stearic acid nanoparticles; edelfosine loaded Compritol® 
nanoparticles; unloaded stearic acid nanoparticles; unloaded Compritol® nanoparticles. 
Fig. 3 depicts the DSC thermograms of edelfosine loaded and unloaded lyophilised 
nanoparticles. DSC analysis of edelfosine-loaded lipid nanoparticles showed that the 
drug melting peak at 223ºC is present neither in the stearic acid lipid nanoparticles nor 
in the Compritol® lipid nanoparticles whereas for the pure drug, the melting peak occurs 
before its decomposition. This thermal behaviour may be ascribed to the presence of 
edelfosine in an amorphous form or molecularly dispersed. This effect on the crystalline 
habit of edelfosine may be related to the preparative method of the lipid nanoparticles, 
in which edelfosine may be turned from a crystalline state to an amorphous one by the 
use of organic solvents like chloroform or methylene chloride. 
 Thermal behaviour of lipids can also explain the different encapsulation efficiency 
of edelfosine. Unloaded stearic acid nanoparticles showed the melting peak of the 
stearic acid at 59 ºC, indicating its presence in crystalline state, thus letting less amount 
of drug to be incorporated among its lipidic chains. On the other hand, Compritol® 
nanoparticles seem to lose part of their crystalline state, permitting edelfosine to fit in 
the molecular gaps. These findings were confirmed by X-ray diffractometry assays. 
Unloaded stearic acid nanoparticles (Fig. 4A) show two sharp peaks corresponding to 
those of the stearic acid, whereas the diffraction pattern of Compritol® (Fig. 4B) showed 
a typical double peak that is significantly modified when formulated into nanoparticles. 
Comparing these results with edelfosine loaded lipid nanoparticles, some crystalline 
drug signal could still be detected, indicating a possible coexistence of edelfosine in 
both crystalline and amorphous states, being this last one the predominant. As a result, 
edelfosine would enrich the particle surface when formulated with stearic acid, whereas 
it would be incorporated among the lipid chains of Compritol®.  
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3.5 In vitro release studies 
The amount of edelfosine released from lipid nanoparticles was determined by an in 
vitro release assay, in an effort to assess whether edelfosine–incorporating lipid 
nanoparticles might be useful as a sustained-release dosage form. 
Fig. 5 displays the release profiles for nanoparticles fabricated with stearic acid or 
Compritol® using 1 % Tween 80 as emulsifier. When edelfosine was incorporated in 
stearic acid nanoparticles, a 63% burst release of the drug was observed within 20 
minutes (Fig.5). Conversely, the initial release burst for nanoparticles prepared using 
Compritol® was less than 40 % within the first 20 minutes. The reason for the high 
initial release of edelfosine from the stearic acid nanoparticles could be the diffusion 
release of edelfosine distributed near the surface and in the outer portion of the 
nanoparticles [12]. These results were in accordance with the observations made by 
DSC and X-ray diffractometry. 
Afterwards, the release rate slowed for both formulations, reaching 55 % after 24 h 
for nanoparticles prepared with Compritol®, and 98 % for the stearic acid nanoparticles.  
The release of a drug from the dosage form implies a crucial step, which is the 
dissolution of the drug. This process is ruled by a release rate constant (kd) that can be 
easily estimated and it is different depending, among other factors, on the composition 
of the particle. In our study, this constant was estimated for the release of edelfosine 
from lipid nanoparticles formulated either with stearic acid or Compritol®. 
Results showed that there is a different release profile depending on the lipid. 
Stearic acid presents a higher release rate constant (kd = 0.208) than Compritol® (kd = 
0.178), indicative of a faster release. Besides, there seems to be no influence of the 
amounts of surfactant employed in the release kinetics of the drug, since the release rate 
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constant from nanoparticles prepared with different surfactant concentrations (0.5 or 1% 
Tween 80) were equivalent. 
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4. Conclusions 
The present research paper proposed a novel formulation for edelfosine by using 
lipid nanoparticles. It can be concluded that Compritol® presents advantages as a matrix 
material for the manufacture of the nanoparticles and the controlled release of 
edelfosine. 
Current studies are aimed at evaluating the in vitro (in cell lines) and in vivo efficacy 
of these newly developed formulations. 
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